Huminsulin Profil Iii Kwikpen

Active Ingredient:: Insulin Human
Origin:: EU

Huminsulin Profil Iii Kwikpen (Insulin Human)

Q: What is Huminsulin Profil Iii Kwikpen and how does it differ from other insulin pens?

Huminsulin Profil Iii Kwikpen is a disposable prefilled pen that contains human insulin. It provides a short‑acting insulin formulation approved in the EU, and its pen design offers a fixed dose per injection without the need for manual dialing.

Q: How is Huminsulin Profil Iii Kwikpen administered?

The pen is used for subcutaneous injection, typically into the abdomen, thigh, or upper arm. The patient or caregiver presses the dose button to deliver the prescribed units, then discards the pen after the in‑use period expires.

Q: Which patients are appropriate candidates for Huminsulin Profil Iii Kwikpen?

It is prescribed for adults and children with type 1 or type 2 diabetes who require a rapid‑acting insulin to control post‑prandial glucose or to correct hyperglycemia.

Q: What are the common side effects of Huminsulin Profil Iii Kwikpen?

Common adverse effects include mild hypoglycemia, injection‑site redness, swelling, itching, lipodystrophy from repeated use at the same site, and modest weight gain.

Q: How should I store Huminsulin Profil Iii Kwikpen before use?

Store the unopened pen in a refrigerator (2‑8 °C). Once removed, it may be kept at controlled room temperature (up to 30 °C) for the period specified by the manufacturer, usually 28 days, and should not be frozen.

Q: Can Huminsulin Profil Iii Kwikpen be used during pregnancy?

Use during pregnancy is possible only under close medical supervision. The benefits must be weighed against potential risks, and dosage may need adjustment based on glucose monitoring.

Q: What should I do if I experience hypoglycemia while using Huminsulin Profil Iii Kwikpen?

Treat mild hypoglycemia promptly with fast‑acting carbohydrates such as glucose tablets or juice. If symptoms are severe or consciousness is lost, seek emergency assistance and administer glucagon if available.

Q: Are there any drug interactions I need to watch for with Huminsulin Profil Iii Kwikpen?

Yes. Concurrent use of other rapid‑acting insulins, beta‑blockers, high‑dose steroids, sulfonylureas, meglitinides, ACE inhibitors in renal impairment, and excessive alcohol can alter glucose control and should be managed carefully.

Q: How often should the injection site be rotated with Huminsulin Profil Iii Kwikpen?

Rotate injection sites within the same region (e.g., abdomen) each time to reduce lipodystrophy. Avoid injecting into the same exact spot for at least several days.

Q: What is the mechanism of action of insulin human in Huminsulin Profil Iii Kwikpen?

Insulin human binds to insulin receptors on muscle, fat, and liver cells, activating the PI3‑K/Akt pathway, which promotes glucose uptake via GLUT‑4 translocation and suppresses hepatic glucose production.

Huminsulin Profil III Kwikpen is a prefilled, disposable insulin pen that contains insulin human as its active ingredient. It is supplied in a ready‑to‑use format for subcutaneous (or occasional intramuscular) injection and is marketed in the European Union by prescription. As a short‑acting insulin in the antidiabetic class, it is intended to replace or supplement endogenous insulin in patients with diabetes mellitus and requires proper technique.

Manufacturer / TM Owner

Lilly Deutschland Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Huminsulin Profil III Kwikpen is indicated for the management of blood glucose in adults and children with diabetes mellitus who require short‑acting insulin therapy.

Initiation or adjustment of basal‑bolus insulin regimens.
Post‑prandial glucose control after meals.
Correction of hyperglycemia when rapid insulin action is needed.
Use during pregnancy or lactation under medical supervision (if prescribed).
Transition from other short‑acting insulin formulations.

How It Works

Insulin human in Huminsulin Profil III Kwikpen binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, which increases glucose uptake. In the liver, the signaling cascade suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose levels. The rapid onset of action aligns with the timing of meals, providing timely glucose disposal.

Side Effects

Adverse reactions to Huminsulin Profil III Kwikpen are reported in clinical use and can be grouped by frequency.

Common

Mild hypoglycemia (blood glucose <70 mg/dL)
Injection site redness, swelling or itching
Lipodystrophy at repeated injection sites
Transient weight gain

Serious

Severe hypoglycemia with loss of consciousness
Allergic reactions such as urticaria or angioedema
Anaphylactic shock (rare)
Persistent hyperglycemia indicating insulin resistance

Precautions & Warnings

When prescribing or using Huminsulin Profil III Kwikpen, clinicians should consider several precautionary measures to ensure safe and effective therapy.

Verify patient’s diagnosis of diabetes and need for short‑acting insulin.
Assess for history of severe hypoglycemia or hypoglycemia unawareness.
Monitor renal or hepatic impairment, which may alter insulin clearance.
Educate patients on proper injection technique and rotation of sites.
Review concomitant medications that affect glucose levels.
Caution in pregnancy, lactation, or pediatric patients; use only if benefits outweigh risks.
Store the pen at controlled temperature and discard after the in‑use period.

Avoid Interactions

Huminsulin Profil III Kwikpen may interact with other agents that influence blood glucose or insulin metabolism; awareness of these interactions helps prevent adverse outcomes.

Avoid

Concurrent use of other rapid‑acting insulins without dose adjustment.
Beta‑blockers that mask hypoglycemia symptoms.
High‑dose corticosteroids that markedly raise glucose levels.

Use with caution

Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
ACE inhibitors or ARBs in patients with renal impairment.
Alcohol consumption, which can cause delayed hypoglycemia.

Frequently Asked Questions

Huminsulin Profil Iii Kwikpen is a disposable prefilled pen that contains human insulin. It provides a short‑acting insulin formulation approved in the EU, and its pen design offers a fixed dose per injection without the need for manual dialing.

The pen is used for subcutaneous injection, typically into the abdomen, thigh, or upper arm. The patient or caregiver presses the dose button to deliver the prescribed units, then discards the pen after the in‑use period expires.

It is prescribed for adults and children with type 1 or type 2 diabetes who require a rapid‑acting insulin to control post‑prandial glucose or to correct hyperglycemia.

Common adverse effects include mild hypoglycemia, injection‑site redness, swelling, itching, lipodystrophy from repeated use at the same site, and modest weight gain.

Store the unopened pen in a refrigerator (2‑8 °C). Once removed, it may be kept at controlled room temperature (up to 30 °C) for the period specified by the manufacturer, usually 28 days, and should not be frozen.

Use during pregnancy is possible only under close medical supervision. The benefits must be weighed against potential risks, and dosage may need adjustment based on glucose monitoring.

Treat mild hypoglycemia promptly with fast‑acting carbohydrates such as glucose tablets or juice. If symptoms are severe or consciousness is lost, seek emergency assistance and administer glucagon if available.

Yes. Concurrent use of other rapid‑acting insulins, beta‑blockers, high‑dose steroids, sulfonylureas, meglitinides, ACE inhibitors in renal impairment, and excessive alcohol can alter glucose control and should be managed carefully.

Rotate injection sites within the same region (e.g., abdomen) each time to reduce lipodystrophy. Avoid injecting into the same exact spot for at least several days.

Insulin human binds to insulin receptors on muscle, fat, and liver cells, activating the PI3‑K/Akt pathway, which promotes glucose uptake via GLUT‑4 translocation and suppresses hepatic glucose production.

Reduced kidney function can slow insulin clearance, increasing the risk of hypoglycemia. Dose adjustments and more frequent glucose monitoring are recommended for patients with moderate to severe renal impairment.

Yes, Huminsulin Profil Iii Kwikpen is a prescription‑only medication in the European Union and must be obtained through a licensed healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 25 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.